Open AccessEpigenetic regulation of cathepsin L expression in chronic myeloid leukaemia
Author(s) -
Samaiya Misti,
Bakhshi Sameer,
Shukla Abhay A.,
Kumar Lalit,
Chauhan Shyam S.
Publication year - 2011
Publication title -
journal of cellular and molecular medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.44
H-Index - 130
eISSN - 1582-4934
pISSN - 1582-1838
DOI - 10.1111/j.1582-4934.2010.01203.x
Subject(s) - cathepsin l , peripheral blood mononuclear cell , biology , cancer research , microbiology and biotechnology , immunology , medicine , cathepsin , genetics , in vitro , biochemistry , enzyme
Abstract The expression and significance of cathepsin L (CTSL) has been extensively studied in solid tumours. However no such information in chronic myeloid leukaemia (CML) was available. We investigated the activity and expression of this protease in peripheral blood mononuclear cells (PBMCs) of 47 adult CML patients. Thirty adults suffering from systemic diseases and 50 healthy volunteers served as controls. The mRNA levels of CTSL, its specific endogenous inhibitor cystatin C and transcriptional up‐regulator vascular endothelial growth factor (VEGF) were quantitated by real‐time qPCR. CTSL protease activity and its mRNA expression were significantly higher in CML chronic phase (CP) patients compared to CML accelerated phase/blast crisis (AP/BC) patients and controls ( P ≤ 0.001). VEGF whose expression was most pronounced in CP and declined ( P ≤ 0.001) in the advanced phases of the malignancy exhibited a strong positive correlation with CTSL expression ( r = 0.97; P ≤ 0.001). Cystatin C expression was significantly lower ( P ≤ 0.001) in CML and displayed inverse correlation with CTSL ( r =−0.713; P ≤ 0.001) activity. CTSL promoter was significantly hypomethylated in CML CP compared to CML AP/BC patients as well as controls. K562, a BC CML cell line displayed CTSL activity, expression and methylation status of CTSL promoter that was comparable to CML AP/BC patients. Treatment of these cells or PBMCs isolated from CML AP/BC patients with 5′‐aza‐cytidine resulted in a dramatic increase in CSTL activity and/or expression thereby demonstrating the role of promoter methylation in the stage specific expression of CTSL in CML. Differential expression of CTSL in CML at various stages of malignancy may prove useful in identification of the high‐risk patients thereby facilitating better management of disease.